[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostate-cancer-non-metastatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostate-cancer-non-metastatic":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100629665","phase-3-radiotherapy-after-prostatectomy-for-node-positive-prostate-cancer-100629665",false,"NCT07477626","Radiotherapy After Prostatectomy for Node Positive Prostate Cancer","Radiotherapy and Androgen Deprivation Therapy Versus Androgen Deprivation Therapy Alone After Prostatectomy for Node Positive Prostate Cancer (RADVAN): A Multicenter, Randomized Controlled Phase Ⅲ Trial","RADVAN","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically confirmed adenocarcinoma of the prostate.\n* Radical prostatectomy with pelvic lymph node dissection and pathologically confirmed positive pelvic lymph nodes (AJCC 8th edition: external iliac, internal iliac, obturator, presacral, periprostatic, and\u002For perirectal nodes).\n* ECOG performance status 0-2.\n* Started postoperative GnRH agonist or antagonist therapy for less than 1 year if receiving postoperative androgen deprivation therapy\\*.\n* Adequate major organ function, defined as:\n\nHemoglobin ≥ 90 g\u002FL Platelet count ≥ 75 × 10⁹\u002FL Total bilirubin ≤ 3 × ULN AST or ALT ≤ 5 × ULN\n\n* Use of effective contraception during the study and for 3 months after.\n* Written informed consent provided, with willingness and ability to comply with study visits, treatments, and procedures.\n\n  * Prior postoperative ARAT use ≤ 3 months is eligible after treatment discontinuation.\n\nExclusion Criteria:\n\n* Measurable pelvic recurrence on postoperative MRI or CT (RECIST 1.1, including prostate bed and lymph nodes).\n* Radiographically confirmed distant metastasis (M1a, M1b, or M1c).\n* Neoadjuvant hormonal therapy \\> 3 months before prostatectomy.\n* Malignancy within 5 years that may interfere with study safety or efficacy assessments.\n* Castration-resistant prostate cancer (CRPC) prior to enrollment per 2025 EAU criteria\n* Prior radiotherapy overlapping irradiation fields that may compromise normal tissue.\n* Serious comorbidities affecting study treatment.\n* Psychiatric disorders preventing understanding or compliance.\n* Any condition that, in the investigator's judgment, makes participation unsuitable.","MALE","18 Years",{"count":20,"type":21},372,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this clinical trial is to evaluate whether the addition of pelvic radiotherapy to androgen deprivation therapy (ADT) can delay disease progression and improve survival outcomes in patients with pathologically confirmed regional lymph node-positive (pN1) prostate cancer after radical prostatectomy.\n\nThe main questions it aims to answer are:\n\n* Does ADT combined with pelvic radiotherapy improve biochemical recurrence-free survival (bRFS) compared with ADT alone in pN1 patients?\n* Does the addition of pelvic radiotherapy improve clinical progression-free survival, metastasis-free survival, overall survival, and prostate cancer-specific survival without unacceptable toxicity?\n\nResearchers will compare ADT plus pelvic radiotherapy with ADT alone to see if combined treatment improves disease control and long-term clinical outcomes.\n\nParticipants with positive lymph nodes after prostatectomy will be randomly assigned in a 2:1 ratio to receive ADT plus pelvic radiotherapy, or ADT alone. ADT will be administered for 2 years. Patients with radiologically detectable pelvic recurrence or distant metastases after radical prostatectomy will be excluded. Safety, adverse events, and health-related quality of life will be assessed during follow-up.",[27,28,29,30,31],"Prostate Cancer (Post Prostatectomy)","Radiotherapy; Image-Guided","Prostate Cancer Non-Metastatic","Androgen Deprivation Therapy","Lymph Node Positive",[33,34,35,36,37,38,39],"prostate cancer","node positive","pN1","radiotherapy","androgen deprivation therapy","hormone therapy","prostatectomy","RECRUITING","2026-06-15",{"date":43,"type":44},"2026-06-16","ACTUAL",{"date":46,"type":44},"2026-03-20",{"date":48,"type":21},"2038-12-31",{"name":50,"class":51},"Sun Yat-sen University","OTHER",13,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100624282","ablative-radiotherapy-for-unfavorable-prostate-tumors-20-100624282","NCT07407608","ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0","Single-Dose Image-Guided Radiotherapy (IGRT) With Focal Boost to the MRI-defined Macroscopic Tumor Volume for Intermediate Unfavorable and High Risk Prostate Cancer","ABRUPT 2","Inclusion Criteria:\n\n* Histologically proven prostate adenocarcinoma;\n* Intermediate and High risk disease, as per the NCCN definition;\n* a PI-RADS 3-5 dominant intraprostatic lesion on multiparametric MRI (mpMRI);\n* N0M0 at staging with standard techniques (Bone Scan and Abdominal CT) or (preferably) PSMA PET-CT;\n* World Health Organization performance status 0-1;\n* Life expectancy of \\> 5 years, in the opinion of the investigator;\n* IPSS score must be ≤ 15 (alpha blockers allowed);\n* Prostate gland volume ≤100 g as estimated by computed tomography (CT), ultrasound, or MRI.\n\nExclusion Criteria:\n\n* ≥T3b disease according to the 8th AJCC classification;\n* PSA\\>20 ng\u002Fml;\n* Previous local treatment of the prostate with surgery (radical prostatectomy or cryotherapy) or transurethral resection;\n* Previous radiotherapy to the pelvis;\n* Presence of a periurethral dominant lesion;\n* Previous invasive malignancy unless disease free for a minimum of 5 years;\n* Active Crohn's Disease or Ulcerative Colitis;\n* Presence of hip prostheses.","90 Years",{"count":63,"type":21},58,"OBSERVATIONAL","Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy tissues is critically assessed with fulfillment of strict constraints and dose distribution is accomplished using image guidance and tracking tools. In the present trial, intermediate unfavorable and selected high-risk organ-confined prostate cancer patients will undergo Single Dose Radiation Therapy (SDRT) With Focal Boost to the MRI-defined Macroscopic Tumor Volume by means of image-guided volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) and state-of-the-art treatment-planning and quality assurance procedures. Androgen Deprivation Therapy (ADT) type and duration has been set as per standard of care, in accordance with current recommendations and guidelines. The results of the study will enable us to find out if the new, shorter treatment (1 doses of radiotherapy), has a similar level of side effects as the 5 dose treatment and is suitable for further study.",[67,68,29],"Prostate Cancer","Prostate Cancer (Adenocarcinoma)",[70,71,72,73,74,75],"Unfavorable Prostate Tumors","Stereotactic Body Radiotherapy (SBRT)","Volumetric Modulated Arc Therapy (VMAT)","Prostate Imaging Reporting and Data System (PI-RADS)","Toxicity","Quality of Life","2026-02-09",{"date":78,"type":44},"2026-02-12",{"date":80,"type":44},"2026-01-28",{"date":82,"type":21},"2034-07-31",{"name":84,"class":51},"University of Milano Bicocca",1]